[A24-73] Alectinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V
Last updated 15.10.2024
Project no.:
A24-73
Commission:
Commission awarded on 04.07.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adjuvant treatment following complete tumour resection for adult patients with anaplastic lymphoma kinase-positive non-small cell lung cancer at high risk of recurrence
- Patients for whom adjuvant platinum-based chemotherapy is suitable: added benefit not proven
- Patients after prior platinum-based chemotherapy or patients for whom this therapy is not suitable: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-73
| Project no. | Title | Status |
|---|---|---|
| A17-19 | Alectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-67 | Alectinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |